Lonza Group Ltd
LONN: XSWX (CHE)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
CHF 228.00 | Yqlsfk | Czqqkmqk |
Lonza Reports Strong Year-End Results; Maintaining FVE of CHF 620, Shares Undervalued
Lonza reported solid year-end results driven by strong underlying performance across its biologics, small molecules, and cell & gene businesses. Fiscal 2022 revenue totaled CHF 6.2 billion, which represents a 15% increase year over year. We maintain our fair value estimate of CHF 620 per share and view shares as undervalued, currently trading in 4-star territory about 15% below our fair value estimate. We maintain our narrow economic moat rating and stable moat trend.